Program

Delivery of Nucleic Acid Therapeutics II: Biology, Engineering and Development

April 4 – 8, 2024
Grand Hotel Minareto
Siracusa, Sicily, Italy

Conference Chairs:

Steven F. Dowdy
UCSD School of Medicine
USA

Laura Sepp-Lorenzino
Intellia Therapeutics
USA

Matt Stanton
Generation Bio
USA

Engineering Conferences International
369 Lexington Avenue, 3rd Floor #389
New York, NY 10017, USA
www.engconfintl.org – info@engconfintl.org
Grand Hotel Minareto

Via del Faro Massolivieri
26 96100 Siracusa
Italy
Tel. +39 0931.721222
Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

ECI BOARD MEMBERS

Eugene Schaefer, Chairman
Paula Alves
Mike Betenbaugh
Joye Bramble
Barry C. Buckland
Nick Clesceri
Chetan Goudar
Peter Gray
Michael King

Chair of ECI Conferences Committee: Nick Clesceri

ECI Technical Liaison for this conference: Joye Bramble

ECI Executive Director: Barbara K. Hickernell
ECI Associate Director: Kevin M. Korpics
ECI Conferences Manager: Tressa D'Ottavio
ECI Registrar: Kathy Chan

©Engineering Conferences International
Previous conferences in this series:

Oligonucleotide Delivery: Biology, Engineering and Development
October 7-11, 2012
Hernstein, Austria
Conference Chairs:
Laura Sepp-Lorenzino, Merck & Co., Inc., USA
Steve Dowdy, UCSD School of Medicine, USA
Conference Sponsors

Alnylam Pharmaceuticals
Arcturus Therapeutics
Avidity Biosciences, Inc.
Dyne Therapeutics
Generation Bio
Intellia Therapeutics
Limelight Bio, Inc.
Korro
MiNA Therapeutics Limited
Moderna
NanoVation Therapeutics
Sirnaomics
Takeda
Thermo Fisher Scientific
TriLink BioTechnologies
Deliverying opportunity through innovation.

Arcturus offers a community that fosters growth and diversity to excel at the discovery, development and commercialization of therapeutics for rare diseases and vaccines.

Explore our technology at arcturusrx.com/rna-medicines, and current opportunities at arcturusrx.com/careers.
To those who say “impossible, impractical, unrealistic,” we say:

CHALLENGE ACCEPTED

We are the leader in RNAi therapeutics – an entirely new class of medicines based on Nobel Prize-winning science. Our R&D efforts are focused on rare genetic, cardio metabolic, hepatic infectious, and CNS and ocular diseases.

Ania, living with rare disease

alnylam.com

© 2020 Alnylam Pharmaceuticals, Inc.
The muscle to

*keep life moving™*

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD).
We’re pushing the limits of genetic medicine.

And our goal is no limits.

At Generation Bio, we are innovating non-viral genetic medicines to provide durable and redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. We are developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). With our platforms, we aim to develop the next wave of non-viral genetic medicines to support our mission to extend the reach of genetic medicine to more people living with more diseases, around the world.

For more information, please visit generationbio.com.
Change Life Stories
with gene editing

Intellia Therapeutics is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies.

LEARN MORE: INTELLIA TX.COM
Better Health, Brighter Future

There is more that we can do to help improve people’s lives.

Driven by passion to realize this goal, Takeda has been providing society with innovative life-changing medicines since our founding in 1781.

As a leading global biopharmaceutical company, Takeda will always be unwavering in our contribution to bring better health and a brighter future to people worldwide.
CleanCap® demonstrates superior performance versus legacy co-transcriptional capping methods

<table>
<thead>
<tr>
<th>Legacy Cap Analogs</th>
<th>CleanCap®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural Cap</td>
<td>No</td>
</tr>
<tr>
<td>Immunogenic</td>
<td>Yes</td>
</tr>
<tr>
<td>Capping Efficiency</td>
<td>~70%</td>
</tr>
<tr>
<td>Yield/mL Transcription</td>
<td>1.5 mg/mL</td>
</tr>
<tr>
<td>Cost</td>
<td>3 X</td>
</tr>
<tr>
<td>Available</td>
<td>No</td>
</tr>
<tr>
<td>Therapeutic Licenses</td>
<td>Yes</td>
</tr>
</tbody>
</table>

CleanCap® results in a natural Cap 1 structure that does not stimulate the innate immune system of the host, resulting in unparalleled efficiency in vivo. Legacy co-transcriptional capping methods yield a Cap 0, an immunogenic cap structure that is poorly expressed in vivo.

The results speak for themselves: CleanCap®, the next generation of cap analogs, provide the most active and least toxic mRNA for your in vivo applications.

Be part of the revolution.
For more information visit: trilinkbiotech.com/cleancap

Luciferase mRNA was formulated with Lunar Lipids and injected by tail vein into mice. At 6 hours, luciferase was measured by western blot in mouse liver. Data courtesy of Arcturus Therapeutics.
At Avidity Biosciences, we are driven by our mission: to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapies. We are doing this by realizing the broad and disruptive potential of our Antibody Oligonucleotide Conjugates (AOC™) platform. Beginning with our muscle disease franchise, our programs tackle the root cause of disease. Our innovative pipeline is set to advance and expand into additional cells and tissues, allowing us to address unmet patient needs across a wide range of therapeutic areas.
At MiNA we are pioneering a new class of medicines called small activating RNAs (saRNAs). Through transcriptional activation, they promise a revolution in our ability to modulate previously undruggable targets. Our first saRNA medicine is currently in clinical testing in patients with advanced liver cancer.

Interested in learning more?

Our powerful bioinformatics platform enables the design of saRNAs for specific gene activation of a variety of targets and we are open to discussing R&D collaborations to develop novel therapeutics.

Contact: info@minatx.com
Website: www.minatx.com

OUR MISSION

Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our next-generation platform technologies use lipid nanoparticles for the safe and efficient delivery of nucleic acids to a variety of tissues.
Thursday, April 4, 2024

15:00 – 16:30  Conference check-in (Hotel Lobby)
16:30 – 16:40  Welcome and General Announcements
16:40 – 17:30  Keynote Talk 1:
Living in the world of Nucleic Acid Medicine, the Cinderella Molecules
Mano Manoharan, Alnylam Pharmaceuticals, USA
17:30 – 19:00  Welcome Reception on terrace
19:00 – 20:30  Dinner (Nesos Restaurant)
20:30      Social Hour

NOTES

- Technical and poster sessions will be in the conference center.
- Audio, still photo and video recording by any device (e.g., cameras, cell phones, laptops, watches) is strictly prohibited during the technical sessions, unless the author and ECI have granted prior permission.
- Speakers – Please have your presentation loaded onto the conference computer prior to the session start (preferably the day before).
- Speakers – Please leave at least 3 minutes for questions.
- Please do not smoke at any conference functions.
- Turn your cellular telephones to vibrate or off during technical sessions.
- After the conference, ECI will send an updated participant list to all participants. Please check your listing now and if it needs updating, you may correct it at any time by logging into your ECI account.
Friday, April 5, 2024

07:30 – 09:00  Breakfast Buffet (Nesos Restaurant)

09:00 – 09:25  Setting the Delivery Stage  
Steve Dowdy, UCSD, USA

**Session 1: Clinical Stage Delivery**  
Chair: Art Krieg, USA

09:25 – 09:50  Tfr Ab conjugated oligos for muscle delivery  
Art Levin, Avidity Biosciences, USA

09:50 – 10:15  Tfr-Fab conjugated oligos for muscle delivery  
Oxana Beskrovnaya, Dyne Therapeutics, USA

10:15 – 10:45  Coffee Break

10:45 – 11:10  CRISPR LNPs  
Kristy Wood, Intellia Therapeutics, USA

11:10 – 11:35  Design and Evaluation of Novel ionizable Lipids for RNA Delivery  
Pad Chivukula, Arcturus Therapeutics, USA

11:35 – 11:50  Delivery of a First-in-Class miR-10b Antagomir to Treat Metastatic Cancer: The Long Winding Road from Pre-Clinical Development to Initial Clinical Experience  
Zdravka Medarova, Transcode Therapeutics, USA (Short Talk)

11:50 – 12:05  Splice-switching oligo conjugates for the treatment of Erythropoietic Protoporphyria  
Phil Becker, ETH, Switzerland (Short Talk)

12:05 – 14:00  Lunch (Terrace or Nesos Restaurant, depending on weather)

**Session 2: Endosomal Trafficking and Escape**  
Chair: Steve Dowdy, UCSD, USA

14:00 – 14:25  LNP Endosomal Escape  
Anders Wittrup, Lund University, Sweden

14:25 – 14:50  Harnessing endocytosis to improve the delivery of oligonucleotide-based drugs  
Marino Zerial, Max Plank Institute, Germany

14:50 – 15:15  ENDOSCAPE: Triterpene glycoside conjugates allow efficient endosomal escape of diverse targeted payloads  
Guy Hermans, Supreme Technologies B.V., the Netherlands

15:15 – 15:40  Predictive Ex Vivo Models of LNP Behavior  
Dwight Morrow, Moderna, USA

15:40 – 16:00  Coffee Break

16:00 – 16:25  GalAhead and PNP, double targeting the way forward!  
Jim Weterings, Sirnaomics, China and USA

16:25 – 16:50  Exploring cellular uptake and trafficking of lipid conjugated antisense oligonucleotides  
Emma Kay, AstraZeneca, Sweden (Short Talk)
16:50 – 17:05  Deep learning-enhanced single particle tracking reveals intracellular delivery and escape of oligonucleotides
Nikos Hatzakis, University of Copenhagen, Denmark (Short Talk)

17:05 – 17:30  Round Table on Today’s Lessons Learned

17:30 – 19:00  Poster Session 1 (Conference Center - with beverages)

19:00 – 21:00  Dinner (Sicilian Buffet on Ortigia Terrace)

21:00  Social Hour
Saturday, April 6, 2024

07:30 – 09:00  Breakfast Buffet (Nesos Restaurant)

**Session 3: Delivery Chemistry, Immunity and Escape**
Chair: Masad Damha, McGill University, Canada

09:00 – 09:25  **Lipidated conjugates for CNS delivery**
Anastasia Khvorova, University of Massachusetts, USA

09:25 – 09:50  **Chemical evolution of artificial peptide carriers for nucleic acid delivery**
Ernst Wagner, Ludwig-Maximilian-University of Munich, Germany

09:50 – 10:15  **Selective Organ Targeted (SORT) LNPs: focus on lung delivery and PCD program**
Dan Siegwart, UT Southwestern/ReCode, USA

10:15 – 10:45  Coffee Break

10:45 – 11:10  **Nucleic acid immunity: the key to successful nucleic acid therapeutics**
Gunther Hartmann, University of Bonn Hospital, Germany

11:10 – 11:25  **Designing Thermostable Hermes lipopolyplex nanoparticles for mRNA and synthetic hpDNA delivery**
Amy Walker, 4BaseBio, UK (Short Talk)

11:25 – 11:40  **Visualization of lipid nanoparticle disintegration and localized endosomal membrane damage**
Johanna M. Johansson, Lund University, Sweden (Short Talk)

11:40 – 11:55  **Molecular Nano-Motors (MNMs): A novel delivery modality for oligonucleotides**
Hamutal Ben Dov, Aposense, Israel (Short Talk)

11:55 – 14:00  Lunch (Terrace or Nesos Restaurant, depending on weather)

**Session 4: New Delivery Strategies**
Chairs: Ernst Wagner, Ludwig-Maximilians-Universität, Germany

14:00 – 14:25  **Recent Discoveries in ExtraHepatic Delivery of RNA Cargoes**
Pete Smith, ReNegade, USA

14:25 – 14:50  **Centyrin-targeted siRNA Conjugates for Extra-hepatic Delivery: ABX1100, a CD71 Centyrin-Gys1 siRNA Conjugate for Treatment of Pompe Disease**
Sukumar Sakamuri, Aro Biotherapeutics, USA

14:50 – 15:15  **Engineering Exosomes to Enable and Create Improved Genetic Medicines**
Tony De Fougerolles, Evox Therapeutics Limited, United Kingdom

15:15 – 15:40  **LNP delivery**
Guarav Sahay, Oregon State University, USA

15:40 – 16:00  Coffee Break

16:00 – 16:14  **In Vivo Delivery of RNA Gene Writers to the Liver and Beyond**
William Salomon, Tessera, USA (Short Talk)

16:15 – 16:30  **“I translate, therefore I deliver”: understanding LNP delivery capabilities on a granular scale to reveal therapeutic opportunities**
Charlotte Dunne, Pantherna, Germany (Short Talk)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 – 17:00</td>
<td><strong>Just a Little Delivery Reality Check</strong></td>
</tr>
<tr>
<td></td>
<td>Paul Burke, Burke Bioventures LLC, USA</td>
</tr>
<tr>
<td>17:00 – 18:30</td>
<td>Poster Session 2 (Conference Center with beverages)</td>
</tr>
<tr>
<td>18:30 – 21:00</td>
<td>Dinner (Nesos Restaurant)</td>
</tr>
<tr>
<td>21:00</td>
<td>Social Hour</td>
</tr>
</tbody>
</table>
**Session 5: Non-Viral and Viral Gene Therapy**
Chairs: Matt Stanton, Generation Bio, USA

**09:00 – 09:25**  
AAV delivery  
Dirk Grimm, Heidelberg University Hospital, Germany

**09:25 – 09:50**  
A Modular, Antibody-Based AAV Retargeting Platform For Efficient And Specific In Vivo Gene Delivery  
Leah Sabin, Regeneron, New York, USA

**09:50 – 10:05**  
Development of a human hematopoietic stem cell targeted platform through multiplexed targeting and de-targeting modifications of a common viral gene transfer vector for safe and effective editing of stem cell compartment in vivo. (Short Talk)  
Dmitry Shayakhmetov, Emory University, USA

**10:05 – 10:30** Coffee Break

**10:30 – 10:55** DNA LNP delivery  
Matt Stanton, Generation Bio, USA

**10:55 – 11:20** Targeting mRNA LNPs to New Cell types  
Stefaan De Koker, Etherna, Belgium

**11:20 – 11:45** LNP Structure  
Jay Kulkarni, Nanovation Therapeutics, Canada

**12:00** Boxed Lunch distribution (Hotel Lobby)

**12:45** Meet in lobby for excursion (departing 13:00)

**13:00 – 17:00** Sightseeing excursion to Roman ruins and Old Town Siracusa

**18:00 – 18:10** Poster Awards

**18:10 – 19:00** Keynote Talk 2 The World of LNPs  
Pieter Cullis, University of British Columbia, Canada

**19:15 – 21:30** Gala Dinner (Terrace of Nesos Restaurant)

**21:30** Social Hour

---

**Monday, April 8, 2022**

**07:30 – 09:00** Breakfast Buffet (Nesos Restaurant)

**09:00 – 12:00** Departures
<table>
<thead>
<tr>
<th>Poster Presentations</th>
</tr>
</thead>
</table>
| 1. **Oligophore and Semaphore for extrahepatic delivery of therapeutic RNA**  
Covadonga Paneda, Altamira Therapeutics, Switzerland |
| 2. **AI-driven design of four-component lipid nanoparticles unlocks systemic mRNA delivery to skeletal and cardiac muscles**  
Daniel Quevedo, METiS Therapeutics, USA |
| 3. **Using MD simulations to design more efficient lipid nanoparticles**  
Florian Mann, Bayer AG, Germany |
| 4. **Safe and effective extra-hepatic delivery of DNA and mRNA using the non-viral fusogenix proteolipid vehicle platform**  
John Lewis, Entos Pharmaceuticals, USA |
| 5. **EndoPore: Targeted delivery of nucleic acid therapeutics using pore-forming proteins**  
Vineeta Tripathi, Vitarka Therapeutics Ltd, United Kingdom |
| 6. **Investigating the effect of Lipid Bioconjugates on Gapmer ASO activity and toxicity**  
Gavin Garland, University of Cambridge, United Kingdom |
| 7. **Dechipering endosomal escape of oligonucleotides from Lipid Nanoparticles by the single particle**  
Frank Schulz, University of Copenhagen, Denmark |
| 8. **Uptake of chemically modified antagonirs by lung relevant cell systems**  
Anna Rydzik, AstraZeneca, Sweden |
| 9. **Syringable microcapsules for sustained, localized and controllable siRNA delivery**  
Sean Bedingfield, Eli Lilly, USA |
| 10. **Innovative development of COVID-19 mRNA vaccine using the gold nanoparticle delivery platform**  
Jeehyeon Bae, Chung-Ang University, South Korea |
| 11. **Characterization of triterpene-mediated endosomal escape of cholesterol siRNA**  
Myriam Cerezo-Magaña, Lund University, Sweden |
| 12. **Exploring the Traut's reagent as a versatile bifunctional linker for oligonucleotide conjugates**  
Daniele Addis, Axolabs GmbH, Germany |
Calendar of ECI Conferences

Celebrating 62 years of international, interdisciplinary engineering conferences

2024

January 7-13 23AI INNOVATIVE MATERIALS & METHODS FOR ADDITIVE MANUFACTURING II (IM2AM) (Tomar Portugal)
D. Schmidt (Luxembourg Institute of Science and Technology (LIST); N. Gupta, New York University; E. Eastwood, KCNSC/Honeywell FM&T; B.G. Compton; University of Tennessee, Knoxville; G.M. Gladysz, Los Alamos National Laboratory

February 4-8 24AT ADVANCING MANUFACTURE OF CELL AND GENE THERAPIES VIII (Coronado, CA)
F. Masri, Cell & Gene Therapy Catapult; C. Yeager, Georgia Institute of Technology; G. Maheshwari, BMS; J. Moscariello, BMS

April 4-8 24AC DELIVERY OF NUCLEIC ACID THERAPEUTICS II: BIOLOGY, ENGINEERING AND DEVELOPMENT (Syracuse, Sicily)
L. Sepp-Lorenzino, Intellia Therapeutics; S. F. Dowdy, University of California San Diego School of Medicine; M. Stanton, Generational Bio

April 14-19 24AI ULTRA-HIGH TEMPERATURE CERAMICS: MATERIALS FOR EXTREME ENVIRONMENT APPLICATIONS V (Sicily, Italy)
D. Sciti, Institute for Science and Technology of Ceramics, CNR; L. Silvestroni and F. Monteverde, ISSMC-CNR; J. Binner, Univ. of Birmingham; R. Savino, Univ. of Naples; G. Thompson, Univ. of Alabama; E. Wuchina, Naval Surface Warfare Center

April 28-May 2 24AP CHEMREC I: THERMOCHEMICAL RECYCLING OF PLASTICS (Malaga, Spain)
S. Kersten, University of Twente; M. Pilar Ruiz, Maastricht University; E. Heeres, University of Groningen

May 5-10 20AF SYNTACTIC AND COMPOSITE FOAMS (Riga, Latvia)
G.M. Gladysz and K.K. Chawla, University of Alabama at Birmingham; A. R. Boccaccini, University of Erlangen-Nuremberg; M. Fukushima, National Institute of Advanced Industrial Science and Technology

May 12-16 24AH NANOTECHNOLOGY IN MEDICINE IV: PHYSICAL TRIGGERS AND ADVANCED MATERIALS (Tomar, Portugal)
K. Rege, Arizona State University; S. De Smidt, Ghent University S. Varghese, Duke University

May 19-24 24AA VACCINE TECHNOLOGY IX (Los Cabos, Mexico)
C. Lutsch, Sanofi Pasteur; L. Lua, University of Queensland; F. Godia, Universitat Autònoma de Barcelona; T. Tagmyer, Merck

July 14-18 24AE NANOTECHNOLOGY CONVERGENCE FOR SUSTAINABLE ENERGY, ENVIRONMENT, CLIMATE CHANGE AND HEALTH: A US-AFRICA CONFERENCE (Casablanca, Morocco)
I.C. Escobar, University of Kentucky; A. El-Gendy, University of Texas-El Paso

July 21-25 24AM BIOCHEMICAL AND MOLECULAR ENGINEERING XXIII: ACCELERATING BIOTECH SOLUTIONS TO AID A CHANGING WORLD (Dublin, Ireland)
M. O'Malley, University of California at Santa Barbara; B. Pfleger, University of Wisconsin; V. Roy, GSK

Oct 6-11 24AN NANOMECHANICAL TESTING IN MATERIALS RESEARCH AND DEVELOPMENT IX (Sicily, Italy)
M. Sebastiani, Rome TRE University

Oct 20-24 24AB INTEGRATED CONTINUOUS BIOMANUFACTURING VI (Leesburg, VA, USA)
A. Azevedo, Instituto Superior Técnico; A. Noyes, Apogee Therapeutics; K. Brower, Sanofi

Nov 3-7 24AO MIXED CONDUCTING AND NONSTOICHIOMETRIC COMPOUNDS VII (Tainan, Taiwan)
W. Chueh, Stanford University; K.-Z. Fung, National Cheng Kung University; R. Waser, RWTH Aachen; H. Takamura, Tohoku University

A not-for-profit organization serving the engineering community since 1962 with international, interdisciplinary engineering conferences
2025

March 30-April 3  25AM  MICROBIAL ENGINEERING III (Porto, Portugal)
E. Keshavarz-Moore, University College London; T. Sauer, Sanofi

Late Spring  25AU  SINGLE USE TECHNOLOGIES VII (Europe)
N. Montenay, Sartorius; A. Rayat, University College London; A. DiBenedetto, Roche Genentech

April 27 – May 2  25AC  CELL CULTURE ENGINEERING XIX (Tucson, AZ)
A. Khetan, BMS; M. Yu, Sutro Biopharma; M. Betenbaugh, Johns Hopkins University

Late Spring  25AG  ALKALI ACTIVATED MATERIALS AND GEOPOLYMERS: SUSTAINABLE CONSTRUCTION MATERIALS AND
CERAMICS MADE UNDER AMBIENT CONDITIONS (Finland)
C. Leonelli, Universita’ degli Studi di Modena e Reggio Emilia; J. Yliniemi, University of Oulu; W.M. Kriven, University of Illinois at Urbana-Champaign; J.L. Provis, University of Sheffield; A.R. Boccaccini, University of Erlangen-Nuremberg

May 18-23  25AB  BIO-CHAR IV (Santa Marta, Colombia)
F. Berruti, Western University, Canada; F.C, Janna, The National University of Colombia

May 18-22  25AO  ADVANCES IN OPTICS FOR BIOTECHNOLOGY, MEDICINE AND SURGERY XVIII (Cork, Ireland)
S. Gibbs, M. Skala and S. Andersson-Engels

June 1-6  25AP  POLYMER REACTION ENGINEERING XII (Clearwater, Florida)
I. Konstantinov, The Dow Chemical Company; P. Iedema, University of Amsterdam; M. Grady, Axalta

June 22-27  25AT  THERMAL AND ENVIRONMENTAL BARRIER COATINGS VII (Irsee, Germany)
B.E. Pint, Oak Ridge National Laboratory; E. Opila, University of Virginia; B. Hazel, Pratt & Whitney; Uwe Schulz, German Aerospace Center; Ram Darolia, GE Aviation (retired); B. Harder, NASA

July 2025  25AW  MICRO- AND NANOPLASTICS IN WATER: CHARACTERIZATION, CURE AND PREVENTION (Switzerland)
D. Hunkeler, Aqua+Tech

Oct 12-16  25AD  ELECTROPHORETIC DEPOSITION VIII: FUNDAMENTALS AND APPLICATIONS ((Calabria, Italy)
B. Ferrari, Institute for Ceramic and Glass, Spanish Research Council; A.R. Boccaccini, University of Erlangen-Nuremberg

October 19-24  25AE  ENZYME ENGINEERING XXVIII (Helsinger, Denmark)
J. Woodley, DTU; D. Hededam-Welner, DTU

October 26-31  25AS  CERAMIC MATRIX COMPOSITES III (Yamanashi, Japan)
R. Darolia, GE Aerospace; K. Goto, JAXA; T. Akatsu, Tokyo University of Technology; S. Kitaoka, Japan Fire Ceramics Center; G. Vignoles, University of Bordeaux

November TBA  25AI  BENEFICIATION OF PHOSPHATES X (Hanoi, Vietnam)
(Chair: Patrick Zhang, Florida Industrial and Phosphate Research Institute, USA; Co-Chairs: Phong Vo, Ardaman & Associates Inc, USA; Erika Rova, Yara Suomi Oy, Finland; André Carlos Silva, Federal University of Goiás, Brazil; Ewan Wingate, Bechtel Australia, Australia)

TBA  25AF  CIRCULAR ECONOMY FOR ORGANIC WASTES AND NUTRIENT MANAGEMENT (Cartagena, Colombia)
Gerardo Ruiz-Mercado, EPA; Karina Angelica Ojeda Delgado, University of Cartagena; Eduardo Luis Sanchez Tuiran, University of Cartagena

2026

February TBA  26AT  ADVANCING MANUFACTURE OF CELL AND GENE THERAPIES IX (TBA)
J. Moscariello, BMS

May/June  26-AP  PYROLIQ II – 2023: Pyrolysis and Liquefaction of Biomass and Wastes (TBA)
F. Berruti, ICFAR & Western University; A. Dufour, CNRS, ENSIC; M. Garcia-Perez, Washington State University; W. Prins, University of Ghent

June 7-12  26AW  WASTELCA 5: LIFE CYCLE SUSTAINABILITY ASSESSMENT FOR WASTE MANAGEMENT AND RESOURCE
OPTIMIZATION V (Cetraro (Calabria), Italy)
U. Arena, University of Campania “Luigi Vanvitelli”

2027

TBA Autumn  27-AH  INTERNATIONAL HYDROGEN CONFERENCE: UNDERSTANDING HYDROGEN-MATERIALS INTERACTIONS
(Park City, Utah)
M. Martin, NIST; J. Burns, University of Virginia

A not-for-profit organization serving the engineering community since 1962 with international, interdisciplinary engineering conferences
Engineering Conferences International

Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program that has served the engineering/scientific community since 1962 as successor program to Engineering Foundation Conferences. ECI has received recognition as a 501(c)3 organization by the U.S. Internal Revenue Service and is incorporated in the State of New York as a not-for-profit corporation.

The program has been developed and is overseen by volunteers both on the international Board of Directors and international Conferences Committee. More than 1,900 conferences have taken place to date. The conferences program is administered by a professional staff and the conferences are designed to be self-supporting.

ECI Mission

To serve the engineering/scientific community with international, interdisciplinary, leading edge engineering research conferences

ECI Purposes

The advancement of engineering arts and sciences by providing a forum for the discussion of advances in the field of science and engineering for the good of mankind by identification and administration of international interdisciplinary conferences

To work with engineering, scientific and social science societies and the interested general public to jointly sponsor conferences and to take other actions that will foster complementary programming.

To initiate conferences that will have a significant impact on engineering education, research practice and/or development.

ECI Encouragement of New Conference Topics

The ECI Conferences Committee invites you to suggest topics and leaders for additional conferences and encourages you to submit a proposal for an ECI conference.

Ideally, proposals should be submitted from 18 to 24 months in advance of the conference although the staff can work on a shorter timeline.

The traditional format for an ECI conference is registration Sunday afternoon with technical sessions held each morning and evening through Thursday or Friday noon. Afternoons are used for informal gatherings, poster sessions, field trips, subgroup meetings and relaxation. This format has served well to build important professional networks in many areas.

ECI welcomes proposals for shorter conferences and for conferences which span weekends in order to reduce the number of working days participants are away from their offices.
ECI Works With You

ECI works with conference chairs in two complementary ways. First, an experienced member of the Conferences Committee acts as your technical liaison from the proposal stage through the conference itself. He or she is always available to consult with you on any conference issue.

Second, after your proposal has been approved by the Conferences Committee, the ECI staff will assume responsibility for the administration of the conference.

Your primary responsibilities will be recruiting the organizing committee, developing the technical program and securing third-party funding necessary to support the travel of key speakers.

The responsibilities of ECI’s “full service” staff include -- but are not limited to -- the following:

- Recommend, negotiate, contract and make substantial deposits for housing, meals, meeting space, A/V equipment and tours.
- Maintain web sites for the conference and for submission of abstracts.
- Publicize via electronic and print media.
- Administer all finances including grants, contributions and purchase orders. (ECI makes grant funds available as soon as a grant is approved.) There is no need for chairs to set up a conference bank account or file tax returns for their conference.
- Process all applications and registrations.
- Produce bound program/abstracts book.
- Contract for the publication of print or electronic proceedings, if any.
- Provide on-site staff during the conference.

For more information, please contact the ECI Director at Barbara@engconfintl.org